Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T17:06:56.014Z.
Consensus retrieved: 2026-10-06T11:30:50.958Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T17:06:56.014Z.
Quote observation: 2026-10-06T17:05:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 463be1a1b995a1dfb9509f80aff3bd03150ce45d2105de53d296fe87a8cca28c
Forward PE Ratio (N/A) = Dated Quote Price ($1.92) / Consensus Forward EPS ($-0.91)
FORWARD PE RATIO
N/A
Foghorn Therapeutics Inc.
Market Cap
$112.82M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Foghorn Therapeutics Inc. (FHTX) | $112.82M | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $112.70M | N/A |
| MaxCyte, Inc. (MXCT)vs › | $113.01M | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $113.02M | N/A |
| BGM Group Ltd. (BGM)vs › | $111.14M | N/A |
| Genelux Corporation (GNLX)vs › | $115.24M | N/A |
| Apyx Medical Corporation (APYX)vs › | $110.12M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $115.51M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.04M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $116.80M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.92, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.91 | $-0.97 – $-0.78 | 7 | n/m |
| 2027-12-31 | $-0.93 | $-1.27 – $-0.66 | 7 | n/m |
| 2028-12-31 | $-0.75 | $-1.13 – $-0.55 | 7 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
